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Background: To determine the feasibility and acceptability of lower limb neuromuscular electrical stimulation (NMES)
as a home-based exercise therapy in patients with cancer who could not attend hospital-based exercise training.
Methods: A single-arm prospective pilot study of NMES, applied daily to both quadriceps muscles for six weeks.
Participants were recruited from patients referred to a hospital-based multi-disciplinary supportive care team
specializing in treatment of patients with nutritional depletion and functional decline.
Results: Of the 15 participants who underwent baseline testing, 10 (67%) completed the study and only one (7%)
withdrew because of discomfort due to NMES treatment. 7/10 (70%) of participants used NMES at least three times a
week for the duration of the study. Use of NMES did not lead to significant improvements in physical performance tests.
Conclusions: NMES is a feasible and acceptable intervention for home use in patients with cancer, poor performance
status and metastatic disease. However, whether NMES is an effective strategy to stabilize or improve physical
performance in such patients is not proven.
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Patients with cancer frequently suffer problems common to
other chronic diseases, namely long-lasting sequelae from
their disease and its treatments [1] as well as progressive de-
cline in overall functional status [2,3]. In many chronic med-
ical conditions e.g. chronic obstructive pulmonary disease
(COPD), and congestive heart failure (CHF), exercise-based
rehabilitation programs have a major impact on quality of
life and functional status [4] and are widely deployed as part
of standard clinical care. However, despite growing evidence
that exercise training in cancer patients also contributes to
improved quality of life and tolerance of anti-cancer treat-
ment [5], exercise-rehabilitation has not been generally
adopted for patients with cancer.* Correspondence: thomas.jagoe@mcgill.ca
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unless otherwise stated.Exercise training programs for patients with chronic dis-
eases typically involve hospital-based supervised training
two or three times a week. However, attendance at hospital-
based exercise training is difficult for debilitated patients
with cancer; and though patients with advanced cancer are
willing to exercise they strongly prefer to do so at home
[6,7]. However the beneficial impact of such home-based
training is still unclear and is difficult to measure. For ex-
ample, a recent study of home-based semi-supervised exer-
cise was unsuccessful because of unexpected poor accrual
and high dropout rates [8]. Outside of such studies, commu-
nity or home-based supervised training is often not readily
available for patients with medical conditions. Thus by de-
fault, a self-directed unsupervised home exercise program is
often recommended for patients unable or unwilling to at-
tend hospital training, despite the inherent difficulties in
monitoring exercise adherence and intensity. Other ap-
proaches are therefore needed which can deliver a safe andral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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suitable for use by patients with poor physical function.
Neuromuscular electrical stimulation (NMES) de-
livers a controlled contractile stimulus to underlying
muscles via surface electrodes placed on the skin. It is
widely used for rehabilitation of neurological or ortho-
pedic conditions. NMES is often used to assist with re-
habilitation following joint surgery [9], by helping to speed
up the recovery of muscle strength and joint function.
Moreover, NMES used in conjunction with voluntary con-
traction exercises, accelerates leg muscle strengthening
after knee arthroplasty [10]. More recently NMES has
been assessed for patients suffering chronic medical con-
ditions. In debilitated patients with COPD or CHF, NMES
of the large lower limb muscles was shown to increase
muscle size [11], improve muscular strength and overall
exercise capacity [12-14], facilitate activities of daily living,
and improve quality of life [15].
Despite the evidence for effectiveness of NMES in other
patient populations, relatively few studies have been per-
formed to test the potential usefulness of NMES in pa-
tients with cancer. One case study reported use of NMES
in a single patient with extensive metastatic lung cancer,
who achieved improvements in mobility, function and
quality of life with NMES [16]. Another pilot study used
NMES in a randomized trial involving 16 advanced stage
non-small cell lung cancer patients with good perform-
ance status. Those receiving NMES found it highly accept-
able, but there was only a non-significant trend towards
improvement in leg muscle strength or other measures of
endurance and habitual daily activity [17]. In a follow-up
phase II study, the same authors recruited lung cancer pa-
tients undergoing first-line palliative chemotherapy and
randomized them to NMES intervention (30 patients) or
a control (19 patients) group [18]. In this later study there
was no improvement in the physical function tests (quadri-
ceps strength or physical activity), and a lower than ex-
pected level of adherence. As a result, the authors concluded
that NMES does appear to warrant further study in ad-
vanced lung cancer patients at this stage in their treatment
[18]. This does not rule out a role for NMES to reduce
muscle loss and dysfunction [19] in other patients with can-
cer, but to date there is still little published data on the use
of NMES in patients with cancer in general, especially those
with poor performance status.
The McGill Cancer Nutrition-Rehabilitation Program
clinic at the Jewish General Hospital (CNR-JGH clinic)
in Montréal, is a multi-disciplinary team that specifically ad-
dresses the clinical needs of patients with cancer referred
with weight loss, anorexia, and reduced physical function.
The CNR-JGH clinic uses a comprehensive interdisciplinary
approach to assess and control symptoms, along with indi-
vidualized dietary interventions and exercise training wher-
ever possible. In our experience, hospital-based exercisetraining is very difficult to deliver to patients with poor per-
formance status and those who live far away from the hos-
pital. To address this practical problem, a pilot study was
performed to evaluate the acceptability and feasibility of a
home-based NMES intervention in a heterogeneous group
of patients attending the CNR-JGH clinic, the majority of
whom had advanced stage cancer. The secondary objective
of the study was to assess the impact of the NMES inter-
vention on tests of physical function focused on walking
endurance capacity, lower extremity strength and global
functional performance.Methods
Patient recruitment
Patients were recruited from those referred to the CNR-
JGH clinic for consultation by their treating oncology
teams at the Jewish General Hospital: an urban univer-
sity teaching hospital in Montréal, Québec, Canada.
The participants recruited included both those with im-
paired performance status (PS = 2 or 3) [20] and pa-
tients with better performance who were unable to
attend hospital-based supervised physical rehabilitation
more than once a week due to travel distance or other
similar constraints. Patients were excluded if they had
any cognitive impairment affecting their ability to
apply NMES safely without medical supervision, skin
conditions contraindicating repeated use of surface
electrodes, orthopedic implants in the hip joint, meta-
static lesions to the femur, or electronic implants (e.g.,
pacemakers and defibrillators). Patients who were already
actively participating in a supervised rehabilitation or exer-
cise intervention greater than once a week were also
ineligible.Baseline functional assessment
All assessments, instruction and follow-ups were per-
formed by the study physiotherapist in the CNR-JGH
clinic. Baseline functional evaluation was performed as fol-
lows: a) Walking endurance capacity was assessed with
the 6-minute walk test (6MWT) [21]. If patients were un-
able to walk independently even with standard walking de-
vices (including rolling walking frames) a score of 0 m was
recorded. b) Lower extremity functional strength was
assessed using the repeated Sit-to-Stand (STS) test, as in-
cluded in the Simmonds Functional Assessment Battery
[22]. The patient was instructed to go from sitting to stand-
ing twice in a row as quickly as possible, without the use of
their arms. The test was performed twice and the average
time of the two trials was recorded. c) Global functional
performance status (PS) [20] was recorded based on pa-
tient’s report of their level of physical activity to the study
physiotherapist.
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stimulation (NMES) machine
Participants were instructed on the application of the sur-
face electrodes and the use the portable NMES machine
(Neurotech MediStim, Galway, Ireland). Initial training
was performed to ensure that participants were able to
apply the electrodes and use the device on themselves
without additional assistance. After cleaning the skin with
an alcohol pad, disposable electrodes (EMPI Self-adhesive
Carbon FM electrodes 2”x 2”) were applied to the motor
points of the Vastus Medialis Oblique distally, and over
the midpoint of the quadriceps muscle belly more proxim-
ally [23]. The electrodes placed on each thigh were then
connected to the individual leads of the NMES unit, to
allow for separate intensity control for each quadriceps.
Participants were instructed to use NMES at home for
6 weeks on both quadriceps muscles simultaneously for
30 minutes a day. Stimulation parameters were as follows:
300 ms pulses, 50Hz, alternating 5 s on 5 s off (50% duty).
Stimulation intensity was individually adjusted for each
limb in order to obtain tetanic contraction or maximum
tolerated intensity. In addition, participants were instructed
to voluntarily contract the quadriceps muscles during the
periods of NMES stimulation (active co-contraction) to en-
hance the strengthening effect and improve tolerance of
NMES. Participants were positioned with their legs on a
horizontal surface, and the knee supported on a rolled
towel. They were asked to perform an isometric contraction
of the quadriceps for the duration of the stimulus, by tight-
ening the thigh muscle and pushing the knee down on
towel without lifting the foot. Where appropriate, partici-
pants could progress the co-contraction exercise if their
strength improved. For this second stage they were
instructed to raise their leg off the surface and completely
extend the knee against gravity.
Study completion and adherence with NMES intervention
The study physiotherapist called or met with each partici-
pant at the mid-point (3 weeks) of the study to give add-
itional instruction if needed. Each patient had a maximum
of 6 weeks (42 days) of NMES and the total (days) and %
maximum possible adherence were calculated using the
logs of daily NMES use completed by each patient. Study
completion was achieved if patients completed the assess-
ment at the end of the intervention period. Patient adher-
ence was measured using an intervention diary in which
participants were asked to log their use of the NMES ma-
chine daily, and document any variance from the prescribed
intervention. The percentage of maximum possible adher-
ence was calculated using the total number of days during
the intervention period when the patient could have used
the NMES machine. Thus, if the patient was hospitalized
for 7 days during the study, the % maximum possible ad-
herence was calculated as a proportion of 35 days not 42.Outcome assessments
Primary outcomes
Feasibility was assessed by measuring the proportion of
patients who completed the 6-week intervention, and by
the overall level of adherence achieved over the interven-
tion period. Acceptability of NMES was evaluated at the
end of the 6 weeks by a brief structured questionnaire de-
veloped for this study which was completed by each pa-
tient. The questionnaire used a 5-point Likert scale to rate
their answers from 1 = “strongly disagree”, 2 = “disagree”,
3 = “neutral”, 4 = “agree”, 5 = “strongly agree”.
Secondary outcomes
Physical performance measures were performed at base-
line (PS, 6MWT, STS) and at the end of the study. To de-
termine the effects of adherence with NMES on physical
function parameters, results were compared in patients
with <40% (poor) vs >40% NMES adherence.
Ethics
The study was approved by the Jewish General Hospital
Research Ethics Committee and all participants provided
written informed consent.
Statistical analysis
Comparison between participants who did and did not
complete the study was performed using unpaired t-test
and Fisher’s exact test for continuous and categorical vari-
ables respectively. Assessment of change from before and
after NMES intervention was performed using paired t-
tests or Fisher’s exact test for PS category count data. To
assess factors potentially relevant to adherence and change
in physical performance tests, mean differences were com-
pared using t-tests and differences in counts within cat-
egories were assessed using Fisher’s exact test. All analyses
were performed using R [24].
Results
111 new patients were seen in the CNR-JGH clinic be-
tween June 2010 and July 2011. Of these 52 (47%) were
potentially eligible for the study (poor performance status
and/or inability to attend hospital-based exercise training).
After further screening, 37 patients were approached and
of these 18 (49%) patients were recruited. The reasons that
19 patients were not consented for the study ranged from
medical deterioration (3) or improvement (1), preference
for standard exercise (4), feeling that the study was not of
interest or too burdensome (6), and follow-up and com-
munication difficulties with study coordinator (5). Of
the 18 patients who gave signed consent, three withdrew
from the study and did not proceed to baseline assessment
(Figure 1). Reasons for early withdrawals included: rapid
medical deterioration and death (n = 1), started exercising




• Started own exercise (N=1)




• Medical decline (N=3)
• Intolerant of NMES (N=1)
End study (N=10)
Figure 1 Breakdown of reasons for early and late withdrawals from the NMES study.
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only after consent was obtained (n = 1). The remaining 15
patients underwent baseline function testing and their
demographic and disease characteristics are shown in
Table 1. Two patients with good PS (PS = 1) were also in-
cluded in the study as they were not exercising regularly
and could not attend the usual hospital-based supervised
training sessions. The majority of patients (73%) had
metastatic (stage IV) disease. The most common tumour
types were lung or gastrointestinal cancers, but five pa-
tients had other types of tumours including breast (n = 1),
ovarian (n = 1), endometrial (n = 1) and haematological
(n = 1) malignancy. One additional patient was being
treated with cyclical intravenous chemotherapy for sys-
temic amyloidosis without overt evidence of underlying
malignancy. Overall 67% of the patients were undergoing
active treatment with chemotherapy and 40% were taking,
or had completed within the preceding 14 days, an ex-
tended (≥3 weeks’ duration) course of corticosteroids
(Table 1). Results of functional testing at baseline are shown
in Table 2. As a group, the patients in this study had im-
paired exercise capacity with mean 6MWT of 257m
(50.2% predicted) and mean STS time of 8.0 s, which is 2.6
standard deviations above the mean expected in (i.e. slower
than) healthy individuals of similar age (Table 2).
Feasibility
Completion of the study was achieved by 10 (66.6%) of
the 15 patients. All 15 had baseline assessments, used
the NMES for the 6-week intervention period, and com-
pleted the final assessments. Four of the five late with-
drawals were not due to the NMES intervention, namely:death (n = 1) and deterioration in medical status (n = 3).
Only one patient withdrew because they found they could
not tolerate the local discomfort due to repeated NMES
treatments (Figure 1). For those completing the study the
machine was used for mean(SD) 20.1(13.0) days during
the 42-day study period. When the adherence was adjusted
to account for periods when NMES had to be stopped dur-
ing hospital admissions, this showed that patients used
their machines over half the available time (mean(SD) 54.2
(32.8)%). On closer examination there were in fact three
groups: three poorly adherent patients (mean(SD) use 14.3
(6.3)%), three moderately adherent patients (mean(SD) use
49.4(1.1)%) and four highly adherent patients (mean(SD)
use 87.8(8.7)%) (Figure 2). Thus, 7(70%) patients com-
pleting the study achieved more than 40% adherence:
equivalent to NMES use at least three times a week. In
subsequent analysis to explore the potential impact of
adherence on physical function two groups were defined:
poorly adherent (<40%, n = 3) and adherent (>40%, n = 7)
patients.
Acceptability
Informal feedback during the study was positive about
the use of NMES at home. Furthermore, the acceptabil-
ity of NMES at a group level was captured using the
questionnaires at the end of the study. More than 50%
of patients felt strongly that 6 weeks’ of NMES use was
acceptable (Table 3: C). Furthermore, a majority of pa-
tients reported that NMES was a useful in helping with
activities and symptoms (Table 3: F, G). In addition 50%
of patients were interested in using NMES outside of a
study (Table 3: H).
Table 1 Demographic and disease characteristics of
patients who underwent full baseline assessment






Age yrs 67.9 (9.4) 67.6 (10.9) 68.4 (6.3) 0.88
Body mass index kg/m2 23.1 (4.6) 23.7(4.9) 22.1(4.2) 0.52
N (%)
Sex
M 9 (60) 4 (40) 5 (100)
F 6 (40) 6 (60) 0 (0) 0.04
PS
1 2 (13) 2 (20) 0 (0)
2 6 (40) 4 (40) 2 (40)
3 7 (47) 4 (40) 3 (60) 0.79
Diagnosis
Lung cancer 4 (27) 3 (30) 1 (20)
GI cancer 6 (40) 2 (20) 4 (80)
Other 5 (33) 5 (50) 0 (0) NA
Cancer stage
III 1 (7) 1 (10) 0 (0)
IV 11 (73) 6 (60) 5 (100)
NA 3 (20) 3 (30) 0 (0) NA
Chemotherapy
Y 10 (67) 6 (60) 4 (80)
N 5 (33) 4 (40) 1 (20) 0.60
Recent steroid use
Y 6 (40) 4 (40) 2 (40)
N 9 (60) 6 (60) 3 (60) 1.00
Notes: P indicates result of significance testing (unpaired t-test for means or
Fisher’s exact test for count data) comparing patients who did, or did not,
complete the study.
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Baseline and final assessment results were compared for
Completers (Table 2). Global performance status and
STS appeared somewhat better, but these changes did
not achieve statistical significance (Fisher’s exact test
p = 0.15 comparing categories of PS; mean reduction in
STS = −1.2s, P = 0.3). Only one patient was unable to
perform the 6MWT at baseline, but they had improved
and walked 220m at end of study. However, as a group
there was no change in mean 6MWT distance after the
NMES intervention period (mean difference = −21.1m, P =
0.7) (Table 2). Adherence with NMES might be expected to
be a major determinant of improvement in physical func-
tion, but we were not able to detect any such effect of ad-
herence with the number of patients recruited in this study.
Thus, the patients with poor adherence (<40%, n = 3) did
not have significantly different changes in STS or 6MWT compared to the adherent patients (>40%, n = 7)
(P = 0.56, 0.71 respectively). It was also noted that those
on long term steroids had significantly reduced 6 MWT
at beginning of study (mean(SD): recent steroids 166
(139)m vs no steroids 394(88)m, P = 0.04). We hypothe-
sized that NMES may have a particularly useful role in
promoting improving function in these patients. How-
ever despite a trend towards differential improvement
in patients on steroids, this did not reach statistical sig-
nificance (6 MWT mean(SD) change: recent steroids 35
(184)m, no steroids −59(161)m, P = 0.4). A test of pro-
portions gave similar suggestive but non-significant re-
sults for both change in 6 MWT and PS, e.g. for PS: 3
out of 4 patients who had recently been on an extended
course of oral corticosteroids reported improved PS
compared with only 1 out of 6 non-steroid-treated pa-
tients (Fisher’s exact test, P = 0.19).
Discussion
This is the first report of the use of NMES in patients
with advanced cancer and poor performance status or
other barriers to usual exercise training. Our results
suggest that NMES is feasible and well-tolerated in this
group of patients with advanced cancer who are unable
to attend hospital-based exercise training. Only one pa-
tient (7%) withdrew from the study because they were
unable to tolerate the NMES intervention, whereas four
patients (27%) withdrew or could not complete the
study, because of medical complications or death. Fur-
thermore, qualitative feedback confirmed that home-
based NMES is highly acceptable. There was a wide range
in adherence with NMES over the 6-week period of inter-
vention, but despite this, 70% of patients used the NMES
for at least 40% of the available days. This equates to use
at least three times a week, which is the usual frequency
for standard exercise training programs. Repeated physical
performance testing before and after NMES revealed wide
intra-individual variability. However, there was no im-
provement in objective measurements of exercise function
after NMES intervention (Table 2). Furthermore, no dose-
effect of NMES was demonstrated, as there were no differ-
ences in physical functional outcomes, between adherent
(>40% maximum usage) and poorly adherent (<40% max-
imum NMES usage) patients.
We recognize a number of limitations to interpreting
our results, including the small number of analyzable pa-
tients (10) in this pilot study. The primary study objective
was to assess feasibility and acceptability of NMES in a
variety of cancer patients and for this reason the patients
recruited for the study had a range of pathological types
and stages of cancer. However, as a result the study partic-
ipants also had a widely varying initial functional status
and exercise performance, making it more difficult to reli-
ably detect functional changes attributable to NMES. We
Table 2 Physical performance evaluation results at baseline and after six weeks of NMES intervention
Baseline End of study
All subjects (N = 15)
Withdrawn (N = 5) Completed (N = 10) Pa Completed (N = 10) Difference Pb
Number
PS 1 0 2 0.79# 4 0.15#
2 2 4 4
3 3 4 2
Mean (SD)
6 MWT m 257 (160) 166 (138) 303 (157) 0.11 282 (171) −21.1 (167.7) 0.70
% 50.2 (32.2) 31.0 (24.6) 59.8 (32.2) 0.08 56.0 (34.5) −3.8 (33.3) 0.73
STS s 8.0 (4.3) 7.6 (3.4) 8.2 (4.8) 0.80 7.0 (3.3) −1.2 (3.4) 0.30
S-score 2.6 (2.4) 2.2 (2.0) 2.7 (2.2) 0.69 2.0 (1.8) −0.7 (2.0) 0.30
Notes: Performance status (PS), six-minute walk distance (6MWT) in metres (m) and expressed as % predicted (from [21]), Sit-to-stand (STS) test expressed as seconds (s)
and as a standard score (S-score) value calculated using age range-specific mean and standard deviations for healthy controls (from [22]): positive scores indicates STS
S-scores above the mean. Pa: #Fisher’s exact (for counts) or unpaired t-test (for means) comparing baseline results for patients withdrawn and patients who completed
study. Pb : #Fisher’s exact (for counts) or paired t-test (for means) comparing baseline and final test results for patients who completed the study.
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likely spontaneous changes in outcome measures over the
same time period. In debilitated advanced cancer patients,
progressive physical deterioration may be anticipated. Thus
a reasonable minimal expectation of successful NMES, and
other exercise interventions, would be to inhibit this deteri-
oration, rather than achieve an improvement from baseline.
Without an untreated comparison group we are unable to
say whether there was any indication of this beneficial effect
of NMES in the current study. Due to limited personnel
resources, the same physiotherapist who instructed the
patient in the use of NMES also performed the out-
comes assessments. This raises the possibility of patient
response bias, particularly for reported global perform-

















Figure 2 Histogram of adherence with NMES intervention
during study.Maddocks et al. [18] reported only 15/30 lung cancer
patients receiving palliative chemotherapy completed ap-
proximately 10 week NMES intervention. In contrast to
the present study, they concluded that NMES was not an
acceptable treatment based on a pre-defined 80% group
adherence threshold [18]. However it is notable that in
line with our results only 3(11%) of their patients with-
drew because of NMES discomfort suggesting that the
intervention, per se, is tolerable for the majority. Further-
more, without any correction for periods when patients
were hospitalized etc., 50% of patients in the study by
Maddocks et al. achieved the required three times a
week treatment frequency, and another 3 patients
fell below this threshold because of only one missed
session. We would concur with the authors of that study
who acknowledged that their conclusion, that NMES is
“unacceptable”, may have been based on unrealistically
stringent criteria [18].
Published studies of use of NMES describe a range of
different electrical stimulation protocols [25] and there
is no clear consensus as to the optimal stimulation fre-
quency, electrode placement sites and duty-cycle etc. The
original intention in this study was to use dual stimulation
of quadriceps and gluteus muscles. However, it became
clear that there were both practical and patient acceptabil-
ity difficulties in repeatedly and consistently placing the
gluteus muscle electrodes, especially in very sedentary pa-
tients or those requiring help from caregivers to do so. As
a result a simplified protocol was used with electrical
stimulation of quadriceps only, combined with active vol-
untary co-contraction of the stimulated limb muscles, to
enhance the contractile stimulus. The use of active co-
contraction is novel and proved both practical and accept-
able as demonstrated by the feedback received (Table 3).
Other informal comments received also suggested the
Table 3 Responses to feedback questions for patients completing the study
Question text Median Range
A “NMES was helpful for me” 4 2-5
B “NMES is something patients can be taught to use safely at home” 5 3-5
C “Using the NMES for 6 weeks is acceptable” 5 2-5
D “Using the NMES for 30 mins a day is acceptable” 4 2-5
E “Home NMES was a good intervention for me” 4 2-5
F “Using NMES had a positive impact on my daily activities” 4 2-5
G “Using NMES had a positive impact on my symptoms” 4 2-5
H “If offered outside of a study, I would want to use NMES” 3 2-5
Notes: Allowed responses ranged from 1–5 where 5 = “totally agree” (see Methods).
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cise training even in this limited way.
Our study was not powered to detect differences in the
physical outcome measures and many other confounding
factors, including acute changes in medical status, can in-
fluence the results of the physical performance tests. The
physical outcomes measures adopted (PS, STS, 6MWT)
have been widely used in studies of cancer patients and
are relevant to normal daily functional activities [22]. How-
ever, direct measurements of muscle strength or cross-
sectional area, have been used by other authors [11,14,17],
and these approaches may be more sensitive to detect mod-
est short-term improvements in muscle induced by NMES.
Analysis of pooled data from several different studies of
NMES in chronic medical conditions suggests NMES use
leads to a mean improvement in 6MWT of 40m [26].
However we calculated that 127 patients would be
needed to detect a difference of 40m in 6MWT (effect size
0.25 SD) with 80% power in any future study, without
modifying the entry criteria. This is directly related to the
wide variance in initial 6MWT results. Thus stratifying
analysis or selecting patients with a pre-defined baseline
performance (e.g. by 6MWT distance) would make it eas-
ier to detect subsequent changes after NMES intervention.
High drop-rate rates and the continuing uncertainty
about which patients are most likely to respond to NMES
physiologically, present significant challenges to successful
completion of studies of NMES in cancer patients. It is
noteworthy that many studies in COPD and CHF con-
clude that use of NMES may be best targeted to the most
debilitated patients with very poor function [14]. However
cancer patients who have both advanced disease and im-
paired functional status (e.g. 6MWT <350 m at baseline
[27]) have very poor prognosis, and even short-term stud-
ies in these patients are likely to suffer substantial drop-
outs [3,8] due to medical deterioration and death. In this
pilot study we were not able to confidently identify any sub-
groups of patients who have greater potential to complete
the NMES intervention. Thus patients who did not
complete the intervention had a trend towards lower mean
baseline 6MWT distance (166m Withdrawn vs 303mCompleted, P = 0.11) (Table 2). However, neither this nor
any other demographic or physical function results at base-
line were significantly different between those that com-
pleted and those who were withdrawn from the study
(Tables 1, 2).
One group of patients who may be more likely to benefit
from NMES are those that have taken a recent prolonged
course of corticosteroids, given that corticosteroids are
both widely used in cancer therapy and can cause myop-
athy [28]. Consistent with this notion, the data from this
study did confirm that those patients recently treated with
steroids had poorer function at baseline (6MWT mean
(SD): recent steroids 166(139)m vs no steroids 394(88)m,
P = 0.04). However there was only a non-significant trend
towards a differential improvement in 6MWT in patients
treated with extended courses of steroids. Nevertheless,
further studies of NMES may be warranted to establish if
early use of NMES can be of particular benefit in cancer
patients treated with prolonged courses of steroids. Simi-
larly, it is conceivable that other subgroups of cancer pa-
tients should be considered for more focused studies,
including the more elderly patients with comorbidities [29]
and those being treated with antitumour agents, such as
Sorafenib, which promote muscle loss [30].
Conclusions
The results of the current pilot study suggest that NMES
is both feasible and acceptable in a mixed group of pa-
tients with cancer, most of whom had poor performance
status. This study does not demonstrate that NMES leads
to improved physical functioning in cancer patients with
poor performance status despite the success of NMES in
other chronic diseases and clinical settings. One reason
for the difficulty in detecting functional benefits of NMES
in cancer patients may be their marked heterogeneity in
terms of medical status and physical functioning. As a re-
sult, though it is likely that NMES has a role in achieving
or maintaining optimal functional ability in selected
patients with cancer, this still remains to be confirmed by
future prospective studies. Such studies should be de-
signed to both identify the best candidates for NMES
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